Comparative Pharmacology
Head-to-head clinical analysis: HALDOL versus TREMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALDOL versus TREMIN.
HALDOL vs TREMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol is a typical antipsychotic that blocks dopamine D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways, reducing positive symptoms of schizophrenia. It also has moderate affinity for sigma receptors and weak affinity for serotonin 5-HT2, alpha-adrenergic, and histamine H1 receptors.
Trihexyphenidyl is a centrally acting anticholinergic agent that blocks muscarinic acetylcholine receptors in the basal ganglia, restoring the balance between dopaminergic and cholinergic activity, thereby reducing extrapyramidal symptoms.
Initial: 1-5 mg PO/IM twice daily; titrate up to 5-10 mg/day. Acute agitation: 5-10 mg IM every 1-8 hours. Maintenance: 5-10 mg/day PO/IM. Maximum: 100 mg/day.
1 mg orally 1-2 times daily, gradually increasing by 1 mg every 5-7 days up to 12 mg/day in divided doses. Maximum dose 12 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 21 hours (range 12–37 hours). Extended half-life in chronic administration supports once-daily dosing; dose adjustments required in hepatic impairment.
Terminal elimination half-life: 16 hours (range 12–20 hours) in adults, supporting twice-daily dosing; 35 hours in elderly patients
Renal (approximately 40%, with 1% unchanged; remainder as metabolites) and fecal (approximately 60%, primarily via bile).
Renal: 40% unchanged; fecal: 60% as metabolites
Category C
Category C
Antipsychotic
Antipsychotic